Charles Schwab Investment Management Inc. Has $108.16 Million Stake in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Charles Schwab Investment Management Inc. reduced its holdings in United Therapeutics by 5.3%, now owning 350,858 shares valued at approximately $108.16 million.
• United Therapeutics reported earnings per share of $6.41 for the last quarter, missing analysts' expectations of $6.80, with revenue also slightly below the forecast at $798.60 million.
• The stock has a current consensus rating of "Moderate Buy" with a price target averaging $379.69 from various analysts, despite some recent downgrades.

Charles Schwab Investment Management Inc. lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 5.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 350,858 shares of the biotechnology company's stock after selling 19,682 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.78% of United Therapeutics worth $108,159,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in UTHR. Vanguard Group Inc. raised its holdings in United Therapeutics by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after acquiring an additional 15,312 shares in the last quarter. AQR Capital Management LLC grew its position in United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after acquiring an additional 7,710 shares during the last quarter. Assetmark Inc. grew its position in United Therapeutics by 20.8% during the 1st quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock worth $159,823,000 after acquiring an additional 89,290 shares during the last quarter. Northern Trust Corp grew its position in United Therapeutics by 29.1% during the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock worth $172,487,000 after acquiring an additional 110,298 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in United Therapeutics by 1.9% during the 4th quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock worth $165,490,000 after acquiring an additional 8,577 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. UBS Group increased their price target on United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Cantor Fitzgerald initiated coverage on United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective on the stock. Finally, Wells Fargo & Company decreased their price objective on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $382.00.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $300.00, for a total value of $3,300,000.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $11,034,300. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,681 shares of company stock worth $24,618,359. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 2.8%

Shares of NASDAQ:UTHR traded up $8.33 during midday trading on Wednesday, hitting $309.72. The company had a trading volume of 579,471 shares, compared to its average volume of 663,918. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The stock has a market cap of $13.97 billion, a price-to-earnings ratio of 12.09, a PEG ratio of 4.57 and a beta of 0.57. The firm has a fifty day simple moving average of $295.40 and a 200 day simple moving average of $310.03.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.85 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.